Key facts
- Amplitude Vascular Systems’s last known valuation is $160.7M (Jan 2025).
- It has raised $66.3M across 1 recorded rounds; the latest was Early Stage VC ($23.6M) in Oct 2024.
- Notable investors include MedTech Innovator, Invest Detroit Ventures, Innovation Partnerships, University of Michigan Endowment, BioStar Capital — 7 tracked in total.
- Amplitude Vascular Systems has filed 1 Form D with the SEC, most recently Oct 2024 ($23.6M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Amplitude Vascular Systems
Funding rounds
1 roundsAbout Amplitude Vascular Systems
Operator of an early-stage medical device company intended to focus on treating severely calcified arterial disease. The company's systems use a novel pulsatile mechanism of action to shatter calcium and expand narrowed vessels, all with a single device, enabling medical professionals to provide patients access to advanced treatment.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2017
- Employees
- 7
- Website
- avspulse.com/
- Ownership
- Privately Held (backing)
Amplitude Vascular Systems doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amplitude Vascular Systems shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amplitude Vascular Systems in its N-PORT filings yet. We sweep new filings monthly.